Forlemu Arnold Nongmoh, Nana Sede Mbakop Raissa, Bandaru Praneeth, Gayam Vijay, Moparty Hamsika, Sempokuya Tomoki, Pradhan Faruq, Reddy Madhavi, Olivera Marco
Department of Gastroenterology and Hepatology, The Brooklyn Hospital Center, Brooklyn, NY, USA.
Department of Internal Medicine, Piedmont Athens Regional, Athens, GA, USA.
Int J Hepatol. 2023 May 31;2023:5727701. doi: 10.1155/2023/5727701. eCollection 2023.
Hepatocellular carcinoma (HCC) is a leading cause of cancer morbidity and mortality. Findings of microvascular invasion (MVI) in patients with HCC have emerged as an important prognostic factor for poor survival after tumor resection.
This study evaluated the relation between MVI and HCC within various anatomical Couinaud's segments of the liver.
A multicenter retrospective review of HCC records was conducted from 2012 to 2017. HCC cases were identified using ICD-9 and 10 codes 155, C22.0, and C22.8. HCC patients who underwent liver transplants were included in this study. Liver segment of the location of HCC was obtained from radiographic records, and MVI information was obtained from pathology reports. Segmental distributions of HCC in MVI versus non-MVI groups were compared using Wilcoxon rank sum tests. value was set at <0.05.
We analyzed 120 HCC patients who underwent liver transplantation. The mean age of our cohort was 57 years, and the most common etiology of liver disease was hepatitis C at 58.3%. The median HCC size was 3.1 cm, and MVI was present in 23.3% of the explanted specimens. MVI was 2 to 3 times significantly higher in patients with HCC affecting segments 2 and 3 and segments 4b and 5 ( = 0.01). Moreover, median survival was significantly lower in patients with MVI versus those without MVI (50 vs. 137 months, < 0.05).
MVI was significantly higher in HCC tumors located in liver segments 2 and 3 and 4b and 5, and survival was lower in patients with MVI compared with those without.
肝细胞癌(HCC)是癌症发病和死亡的主要原因。肝细胞癌患者微血管侵犯(MVI)的发现已成为肿瘤切除术后生存不良的重要预后因素。
本研究评估了MVI与肝脏不同解剖Couinaud段内肝细胞癌之间的关系。
对2012年至2017年的肝细胞癌记录进行多中心回顾性研究。使用ICD-9和10编码155、C22.0和C22.8识别肝细胞癌病例。本研究纳入了接受肝移植的肝细胞癌患者。肝细胞癌位置的肝段信息来自影像学记录,MVI信息来自病理报告。使用Wilcoxon秩和检验比较MVI组与非MVI组肝细胞癌的节段分布。P值设定为<0.05。
我们分析了120例接受肝移植的肝细胞癌患者。我们队列的平均年龄为57岁,最常见的肝病病因是丙型肝炎,占58.3%。肝细胞癌的中位大小为3.1 cm,23.3%的切除标本中存在MVI。影响第2和3段以及第4b和5段的肝细胞癌患者的MVI显著高出2至3倍(P = 0.01)。此外,有MVI的患者的中位生存期明显低于无MVI的患者(50对137个月,P < 0.05)。
位于肝段2和3以及4b和5的肝细胞癌肿瘤中的MVI显著更高,与无MVI的患者相比,有MVI的患者生存率更低。